The global PD – L1 biomarker testing market holds a valuation of US$ 597.9 Million by the end of the year 2022. Throughout the forecast period of 2023 to 2033, the market is likely to display growth at a CAGR of 9.14%, and is expected to hold a market value of around US$ 1.58 Billion in 2033.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 597.9 Million |
| Market Value 2023 | US$ 659.6 Million |
| Market Value 2033 | US$ 1.58 Billion |
| CAGR 2023 to 2033 | 9.14% |
| Market Share of Top 5 Countries (2022) | 75.8% |
| Key Market Players | F. Hoffmann - La Roche Ltd., Agilent Technologies, Inc., Abcam plc, Shuwein Biotech Co. Ltd., NeoGenomics Laboratories, Inc., HalioDx, Abcam plc, Merck, Bristol-Myers Squibb, AstraZeneca |
Cancer diagnostics involves detection of specific biomarkers, proteins, and symptoms of cancers in patients that indicate the development of abnormal cancerous cells. The detection make use of specific technology and devices used in its diagnosis. PD-L1 is a protein that helps to keep the immune system in check. In cancerous conditions, this protein is found in higher concentrations.
Cancer has a significant impact on society worldwide. It is one of the world's leading causes of death, with a higher prevalence in developed and emerging markets. According to the article published in a cancer journal for clinicians in 2021 regarding global cancer statistics 2020, International Agency for Research on Cancer estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020 in 185 countries. The alarming rise in cancer prevalence requires healthcare providers to reconsider cancer treatment goals and shift their focus to preventive care.
Rising research activities for the treatment of several cancer indications are expected to bode well for the market. Increasing applications of biomarker testing across abundant tumour types, including an earlier-stage cancer detection is anticipated to provide opportunities for key players to invest and research in the biomarker testing market. The innovation of biomarker testing is finding a new niche in cancer immunotherapy, which will help the market expand.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The PD – L1 biomarker testing market expanded at a CAGR of 6.96% between 2017 and 2022 due to increased awareness of cancer disease, advanced technologies used for cancer diagnosis.
The market value for PD-L1 biomarker testing market was around 1.0% of the overall US$ 67.2 Billion of the global diagnostic biomarkers market in 2022.
PD-L1 biomarker testing is a reliable diagnostic approach in cancer management since it is based on the fact that each person has distinctive levels of the PD-L1 protein. For instance, early stages of non-small cell lung cancer (NSCLC) and melanoma are found using PD-L1 biomarkers in cancer diagnoses and analysis.
The growing availability of high-quality immunotherapy products worldwide is addressing unmet cancer treatment needs. In the current scenario, lifestyle changes such as physical inactivity, tobacco consumption and smoking, as well as an unhealthy diet, are main contributors to the rising burden of cancerous indications.
Key market players are focusing on the development or extension of novel biologics using existing biologic resources for innovative product identification and the provision of patented therapies. Cancer immunotherapy has advanced the diagnostic approach to cancer detection and management, propelling the PD-L1 biomarker testing market forward.
| Market Statistics | Details |
|---|---|
| Jan to Jun (H1), 2021 (A) | 8.30% |
| Jul to Dec (H2), 2021 (A) | 12.06% |
| Jan to Jun (H1),2022 Projected (P) | 8.27% |
| Jan to Jun (H1),2022 Outlook (O) | 9.11% |
| Jul to Dec (H2), 2022 Outlook (O) | 11.69% |
| Jul to Dec (H2), 2022 Projected (P) | 11.06% |
| Jan to Jun (H1), 2023 Projected (P) | 8.30% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 85↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 82↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 63↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (A) | (-) 37↓ |
Principal Consultant
Increasing number of cancer cases worldwide is the key driver to boost the global market. Cancer is at the second place for prevalence in the world. According to World Cancer Research Fund International, detected cancer cases were 18,094,716 million globally in 2020. Prevention of cancer is very challenging and needs an early detection.
The development of reliable PD-L1 biomarker testing with appropriate licensing for use is expected to drive PD-L1 biomarker testing sales in the coming years. Because of PD-L1 biomarker screening tests, the pharmacological diagnosis of cancer were possible. It is helping in production of personalised medicines, thus anticipated to increase the cancer screening biomarkers like PD-L1 biomarker.
The lifestyle choices, dietary habits, and social factors like drinking, smoking, and tobacco habits have dramatically increased in recent years all throughout the world, especially among younger generations. These factors directly adds to the rising incidence of lung cancer around the world. People's awareness of early detection and diagnosis of lung cancer has grown in recent years, and more people are undergoing such tests. This, too, is expected to benefit the market in the forecast period.
The challenges in testing and identifying biomarkers, as well as their validation and implementation in molecular diagnostics, are factors limiting the demand for PD-L1 biomarker testing. Trials including clone evolution, tumour heterogeneity detection, and biomarker testing are also likely to have a detrimental effect on market expansion.
The growth of the PD-L1 biomarker testing market is also hampered by the lack of skilled laboratory technicians because diagnostic laboratories use cutting-edge technology and automation. Despite the availability of advanced tools that make testing simple, critical mistakes regarding the dependability of data across multiple platform, as well as comparable difficulties in analytical validation, will affect sales.
Molecular testing faces considerable obstacles in several regions due to difficulties with regulatory authorities' drug licencing and testing procedures as well as the availability of constrained reimbursement. These characteristics favour on-demand testing, which is expected to restrain the market's expansion for PD-L1 biomarker testing in the years to come.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | The USA |
|---|---|
| Market Share (2023) | 54.3% |
| Market Share (2033) | 57.4% |
| BPS Analysis | 311 |
| Country | The United kingdom |
|---|---|
| Market Share (2023) | 6.8% |
| Market Share (2033) | 7.3% |
| BPS Analysis | 46 |
| Country | Canada |
|---|---|
| Market Share (2023) | 5.6% |
| Market Share (2033) | 4.1% |
| BPS Analysis | -148 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.2% |
| Market Share (2033) | 4.7% |
| BPS Analysis | -54 |
| Country | China |
|---|---|
| Market Share (2023) | 4.5% |
| Market Share (2033) | 5.2% |
| BPS Analysis | 70 |
In 2023, with 54.3% of the market share, the United States will dominate the global market. The country's high prevalence of lung cancer and related chronic illnesses, as well as rising investments in the production of cutting-edge medications, medical technology in the oncology market, and increasing attention on early cancer diagnosis will aid the USA market grow throughout the duration of the forecast period.
According to American Cancer Society, the estimated values for lung cancer in the USA in 2023 are 238,340 new cases of lung cancer about and about 127,070 deaths from lung cancer.
TheUnited kingdom market is anticipated to expand at a 9.9% CAGR over the forecast period, accounting for a significant part of the market for increased PD-L1 testing in the Europe.
Sales in the market are expected to be boosted by the presence of governed predictive testing within the nation under national and regional regulations, awareness of early cancer diagnosis, and technological development. Increasing medical tourism in the United kingdom will further increase the demand for PD-L1 biomarker testing.
According to Cancer Research United kingdom, estimated 167,000 cancer deaths occur in the United kingdom each year due to the high frequency of the disease.
PD-L1 biomarker testing market in China will expand at a CAGR of 10.8% over the forecast period. The need for PD-L1 biomarker testing is being driven by an increase in cancer cases in the nation.
According statistical presentation by GLOBOCAN 2022, there were approximately 4,820,000 new cancer cases identified in China in 2022. Among this number, 2,625,070 men and 2,195,764 women were diagnosed. These metrics support the transitive efforts by the country to present biomarker testing into the overall healthcare structure.
PD-L1 22C3 assay kit demand will hold 49.90% of the overall market share in 2023. Sales in this market will grow during the forecast period due to the efficiency of PD-L1 22C3 tests used in non-small cell lung cancer testing and patients' positive responses to immune checkpoint inhibitors.
Global demand for PD-L1 Biomarker Testing for NSCLC is growing as lung cancer incidence rises. In 2023, the category is set to hold 62.8% of the global market share, and it is anticipated that this pattern will hold in the upcoming years. The availability of PD-L1 protein is the only biomarker, which can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
In terms of end users, 44.1% of the global market share in 2023 will be held by cancer research institutes. The study and development of innovative treatments for oncological purposes across various cancer research centers is gaining traction as the prevalence of cancer-related morbidity increases globally.
The focus of key players is on the development and introduction of novel PD-L1 biomarkers for the treatment of various cancers. Market exclusivity and government incentives to promote new and innovative options for cancer treatment will create lucrative opportunities for market players.
Some recent developments include
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the PD-L1 Biomarker Testing market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value, and Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United kingdom, Germany, Italy, France, Spain, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC countries, Türkiye, South Africa and North Africa. |
| Key Market Segments Covered | Product, Type, Application, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market in 2023 is valued at US$ 659.6 Million
By 2033, the market is expected to reach US$ 1.58 Billion
The market is likely to expand at a 9.14% CAGR through 2033.
From 2018 to 2022, the market record a 6.96% CAGR.
In 2023, the United States accounts for 54.3% revenue.
1. Executive Summary | PD-L1 Biomarker Testing Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption/Usage Analysis
4.2. Key Promotional Strategies, by Manufacturers
4.3. Key Regulations
4.4. PESTEL Analysis
4.5. Porter’s Analysis
4.6. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Diagnostic Biomarkers Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. New Product Launches and Approvals
5.2.3. Adoption rate of Cancer Immunotherapy
5.2.4. Increasing R&D Expenditure by Key Players
5.2.5. Strategic Collaborations among Players
5.2.6. Pipeline Assessment
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Indication
6.1.3. By End User
6.1.4. By Country
6.2. 2022 Market Scenario
7. Global Market Volume (Units) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Volume (Units) Analysis, 2017 to 2022
7.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Material
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
9.2. 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis by Product, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Product, 2023 to 2033
10.3.1. PD – L1 22C3 Assay Kit
10.3.2. PD – L1 28 – 8 Assay Kit
10.3.3. PD – L1 SP142 Assay Kit
10.3.4. PD – L1 263 Assay Kit
10.4. Market Attractiveness Analysis by Product
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis by Indication, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2023 to 2033
11.3.1. NSCLS
11.3.2. Melanoma
11.3.3. Renal Cell Carcinoma
11.3.4. Gastrointestinal Tract Malignancy
11.3.5. Hematological Malignancies
11.3.6. Ovarian Cancer
11.3.7. Other
11.4. Market Attractiveness Analysis by Indication
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis by End User, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2023 to 2033
12.3.1. Hospitals
12.3.2. Diagnostic Laboratories
12.3.3. Cancer Research Institutes
12.4. Market Attractiveness Analysis by End User
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, by Region, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast by Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa
13.4. Market Attractiveness Analysis by Region
14. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Indication
14.4.4. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. USA Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Indication
14.8.1.2.3. By End User
14.8.2. Canada Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Indication
14.8.2.2.3. By End User
15. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Indication
15.4.4. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Mexico Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Indication
15.8.1.2.3. By End User
15.8.2. Brazil Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Indication
15.8.2.2.3. By End User
15.8.3. Argentina Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Indication
15.8.3.2.3. By End User
16. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. United kingdom
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Indication
16.4.4. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Germany Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Indication
16.8.1.2.3. By End User
16.8.2. Italy Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Indication
16.8.2.2.3. By End User
16.8.3. France Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Indication
16.8.3.2.3. By End User
16.8.4. United kingdom Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Indication
16.8.4.2.3. By End User
16.8.5. Spain Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Product
16.8.5.2.2. By Indication
16.8.5.2.3. By End User
16.8.6. BENELUX Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Product
16.8.6.2.2. By Indication
16.8.6.2.3. By End User
16.8.7. Russia Market Analysis
16.8.7.1. Introduction
16.8.7.2. Market Analysis and Forecast by Market Taxonomy
16.8.7.2.1. By Product
16.8.7.2.2. By Indication
16.8.7.2.3. By End User
17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Indication
17.4.4. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Indication
17.8.1.2.3. By End User
17.8.2. Japan Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Indication
17.8.2.2.3. By End User
17.8.3. South Korea Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Indication
17.8.3.2.3. By End User
18. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Indication
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Indication
18.4.4. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. India Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product
18.8.1.2.2. By Indication
18.8.1.2.3. By End User
18.8.2. Indonesia Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product
18.8.2.2.2. By Indication
18.8.2.2.3. By End User
18.8.3. Malaysia Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product
18.8.3.2.2. By Indication
18.8.3.2.3. By End User
18.8.4. Thailand Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Product
18.8.4.2.2. By Indication
18.8.4.2.3. By End User
19. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Indication
19.3.4. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Indication
19.4.4. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. Australia Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Product
19.8.1.2.2. By Indication
19.8.1.2.3. By End User
19.8.2. New Zealand Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Product
19.8.2.2.2. By Indication
19.8.2.2.3. By End User
20. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis Trend Analysis by Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast by Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. North Africa
20.3.1.4. South Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Indication
20.3.4. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Product
20.4.3. By Indication
20.4.4. By End User
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. GCC Countries Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Product
20.8.1.2.2. By Indication
20.8.1.2.3. By End User
20.8.2. Türkiye Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Product
20.8.2.2.2. By Indication
20.8.2.2.3. By End User
20.8.3. South Africa Market Analysis
20.8.3.1. Introduction
20.8.3.2. Market Analysis and Forecast by Market Taxonomy
20.8.3.2.1. By Product
20.8.3.2.2. By Indication
20.8.3.2.3. By End User
20.8.4. North Africa Market Analysis
20.8.4.1. Introduction
20.8.4.2. Market Analysis and Forecast by Market Taxonomy
20.8.4.2.1. By Product
20.8.4.2.2. By Indication
20.8.4.2.3. By End User
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. F. Hoffmann – La Roche Ltd.
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Sales Footprint
22.3.1.4. Key Financials
22.3.1.5. SWOT Analysis
22.3.1.6. Key Developments
22.3.1.7. Strategy Overview
22.3.1.7.1. Marketing Strategy
22.3.1.7.2. Product Strategy
22.3.1.7.3. Channel Strategy
22.3.2. Agilent Technologies, Inc.
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Sales Footprint
22.3.2.4. Key Financials
22.3.2.5. SWOT Analysis
22.3.2.6. Key Developments
22.3.2.7. Strategy Overview
22.3.2.7.1. Marketing Strategy
22.3.2.7.2. Product Strategy
22.3.2.7.3. Channel Strategy
22.3.3. Abcam plc
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Sales Footprint
22.3.3.4. Key Financials
22.3.3.5. SWOT Analysis
22.3.3.6. Key Developments
22.3.3.7. Strategy Overview
22.3.3.7.1. Marketing Strategy
22.3.3.7.2. Product Strategy
22.3.3.7.3. Channel Strategy
22.3.4. Shuwein Biotech Co. Ltd.
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Sales Footprint
22.3.4.4. Key Financials
22.3.4.5. SWOT Analysis
22.3.4.6. Key Developments
22.3.4.7. Strategy Overview
22.3.4.7.1. Marketing Strategy
22.3.4.7.2. Product Strategy
22.3.4.7.3. Channel Strategy
22.3.5. NeoGenomics Laboratories, Inc.
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Sales Footprint
22.3.5.4. Key Financials
22.3.5.5. SWOT Analysis
22.3.5.6. Key Developments
22.3.5.7. Strategy Overview
22.3.5.7.1. Marketing Strategy
22.3.5.7.2. Product Strategy
22.3.5.7.3. Channel Strategy
22.3.6. HalioDx
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Sales Footprint
22.3.6.4. Key Financials
22.3.6.5. SWOT Analysis
22.3.6.6. Key Developments
22.3.6.7. Strategy Overview
22.3.6.7.1. Marketing Strategy
22.3.6.7.2. Product Strategy
22.3.6.7.3. Channel Strategy
22.3.7. Abcam plc
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Sales Footprint
22.3.7.4. Key Financials
22.3.7.5. SWOT Analysis
22.3.7.6. Key Developments
22.3.7.7. Strategy Overview
22.3.7.7.1. Marketing Strategy
22.3.7.7.2. Product Strategy
22.3.7.7.3. Channel Strategy
22.3.8. Merck
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Sales Footprint
22.3.8.4. Key Financials
22.3.8.5. SWOT Analysis
22.3.8.6. Key Developments
22.3.8.7. Strategy Overview
22.3.8.7.1. Marketing Strategy
22.3.8.7.2. Product Strategy
22.3.8.7.3. Channel Strategy
22.3.9. Bristol-Myers Squibb
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Sales Footprint
22.3.9.4. Key Financials
22.3.9.5. SWOT Analysis
22.3.9.6. Key Developments
22.3.9.7. Strategy Overview
22.3.9.7.1. Marketing Strategy
22.3.9.7.2. Product Strategy
22.3.9.7.3. Channel Strategy
22.3.10. AstraZeneca
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Sales Footprint
22.3.10.4. Key Financials
22.3.10.5. SWOT Analysis
22.3.10.6. Key Developments
22.3.10.7. Strategy Overview
22.3.10.7.1. Marketing Strategy
22.3.10.7.2. Product Strategy
22.3.10.7.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
PD-L1 Biomarker Testing Market
